ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Amarin Corp PLC

Amarin Corp PLC (AMRN)

0.5601
0.0352
(6.71%)
At close: February 12 4:00PM
0.5474
-0.0127
( -2.27% )
After Hours: 7:41PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.5474
Bid
0.5401
Ask
0.579
Volume
1,363,951
0.51 Day's Range 0.5893
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.5249
Open
0.51
Last Trade Time
19:41:46
Financial Volume
$ 740,140
VWAP
0.542644
Average Volume (3m)
-
Shares Outstanding
411,338,131
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
306.91M
Net Profit
-59.11M

About Amarin Corp PLC

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa. Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
London, Gbr
Founded
-
Amarin Corp PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AMRN. The last closing price for Amarin was $0.52. Over the last year, Amarin shares have traded in a share price range of $ 0.00 to $ 0.00.

Amarin currently has 411,338,131 shares outstanding. The market capitalization of Amarin is $215.91 million.

AMRN Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

AMRN - Frequently Asked Questions (FAQ)

What is the current Amarin share price?
The current share price of Amarin is $ 0.5474
How many Amarin shares are in issue?
Amarin has 411,338,131 shares in issue
What is the market cap of Amarin?
The market capitalisation of Amarin is USD 215.91M
What is the 1 year trading range for Amarin share price?
Amarin has traded in the range of $ 0.00 to $ 0.00 during the past year
What is the reporting currency for Amarin?
Amarin reports financial results in USD
What is the latest annual turnover for Amarin?
The latest annual turnover of Amarin is USD 306.91M
What is the latest annual profit for Amarin?
The latest annual profit of Amarin is USD -59.11M
What is the registered address of Amarin?
The registered address for Amarin is ONE NEW CHANGE, LONDON, EC4M 9AF
What is the Amarin website address?
The website address for Amarin is www.amarincorp.com
Which industry sector does Amarin operate in?
Amarin operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGOLMGO Global Inc
$ 0.6633
(45.36%)
12.42M
AVGRAvinger Inc
$ 0.6627
(44.07%)
4.16M
TIVCTivic Health Systems Inc
$ 0.925
(32.14%)
39.39M
APPApplovin Corporation
$ 486.0201
(27.79%)
2.27M
BPTHBio Path Holdings Inc
$ 0.8771
(21.82%)
5.47M
OMGAOmega Therapeutics Inc
$ 0.1826
(-29.77%)
4.33M
TTDThe Trade Desk Inc
$ 89.01
(-27.18%)
5.55M
MYNAMynaric AG
$ 0.4899
(-20.98%)
6.8M
ATAIATAI Life Sciences NV
$ 2.09
(-18.04%)
1.22M
NKGNNKGen Biotech Inc
$ 0.69
(-18.03%)
2.13M
TIVCTivic Health Systems Inc
$ 0.925
(32.14%)
39.39M
CYNCYNGN Inc
$ 0.1392
(-7.20%)
32.03M
ADTXAditxt Inc
$ 0.0855
(-6.25%)
17.35M
HOODRobinhood Markets Inc
$ 64.4483
(15.27%)
14.94M
MGOLMGO Global Inc
$ 0.6633
(45.36%)
12.42M

AMRN Discussion

View Posts
seve333 seve333 2 hours ago
How is someone a basher by claiming his prediction of a 100 bucks a share was a really bad prediction. He said Brave was a game changer. He basically keeps telling everyone to load up the boat and he has been saying the same thing for years. I pity anyone who put all their eggs in this one basket like he basically has been telling them to do. It is not a ray of sunshine its pumping and getting people to believe unrealistic expectations and predictions.
👍️0
Monk4444 Monk4444 4 hours ago
Mr. SB
You are a ray of light amongst the dark and demented bashers
here, but most are on ignore anyway so my time is not wasted.
👍️ 1
ProLiberty ProLiberty 5 hours ago
It's falling but what kind of investor decides to buy 400k of stock at once without caring about pushing it up? I have no idea who it might be but strategic, buyback, Sarissa, another hedge fund who wants to bump up a position and can't be bothered to spend time working the $250k add?
👍️0
abka abka 5 hours ago
Keep your confidence on flyfishing.. it is coming down 🙂
👍️0
hayward hayward 5 hours ago
ProLiberty

Ask Flyfishingstocks I am sure he predicted it in his TA prep this morning 😊

Michael
👍️0
ProLiberty ProLiberty 5 hours ago
Why the 11% jump?
👍️0
Birdbrain Ideas Birdbrain Ideas 6 hours ago
It's just you. Last year, Amarin put out a release on Feb. 15 to say that Fourth Quarter earnings would be announced on Feb. 29.
👍️0
Mr Stockboy Mr Stockboy 6 hours ago
Being a genius comes with a great responsibility to disclose I have been buying shares for under $1 for an extended period of time. Amarin continues to extend its revenue fishing net across the globe soon to extend in South America as it gobbles up the rest of the planet. Alex Denner recently said to me in a dream: "Know you've bought the goose that will lay the golden egg." And then he smiled, and disappeared. STRONG BUY
👍️0
Skipperdog11 Skipperdog11 6 hours ago
If they are playing the surprise of good news to possibly assist a portion of the already approved buyback to move the stock north, the company has a lot of latitude around the timing of public disclosure. I'm just a little curious as to why no mention of earnings date has yet to fall.
👍️0
JRoon71 JRoon71 6 hours ago
Amarin's failure to take up some of these charts and use them to the company's advantage just shows me a lack of awareness on Amarin's part that makes me question whether it will ever reach the minds of most doctors.
Either Sarissa/Denner is as smart as everyone seems to think they are, or they are not. If they ARE, then it means they are intentionally holding back from any type of PR/prmotion/marketing. And if that's the case, you must ask yourself why are they doing that?

If they are NOT smart enough to understand the need for corporate self-promotion, then we are obviously in trouble on a grander scale.

You just have to decide which it is.
👍️0
Birdbrain Ideas Birdbrain Ideas 6 hours ago
I agree. Some of the charts that CaptBeer produces are so simple that even I, a total dummy, understand them. Amarin's failure to take up some of these charts and use them to the company's advantage just shows me a lack of awareness on Amarin's part that makes me question whether it will ever reach the minds of most doctors.
👍️0
ramfan60 ramfan60 6 hours ago
No requirement to pre-announce anything as long as information is available to all stakeholders at the same time...... but we know insiders always get advance knowledge and play the game accordingly.
👍️0
rosemountbomber rosemountbomber 7 hours ago
Are companies supposed to pre-announce good as well as bad news or is there hard & fast rule on that?
👍️0
JRoon71 JRoon71 7 hours ago
Yeah, I can't think of another good reason, unless it's bad news and they are just buying time.

But if nothing comes out of this CC to start nudging the SP, then I'm at a loss for what their plan is.
👍️0
roadkilll roadkilll 8 hours ago
wrong board, sorry
👍️0
mrmainstreet mrmainstreet 8 hours ago
What are you going on about?
👍️0
roadkilll roadkilll 8 hours ago
80 P/E would be meme action on a heavily shorted stock with declining sales and declining margins.
170 P/E is what RICO action can do with manipulation with that kind of stock symbol.
👍️0
roadkilll roadkilll 8 hours ago
If you want to find the criminals follow the call action. Someone posted the calls have seen a big upswing. That would be a sign the organized crime Boyz are back at work.
Not that hard for the worthless SEC to track if they were interested in protecting the small investors. That would be the job we pay them to do.
👍️0
Skipperdog11 Skipperdog11 9 hours ago
JRoon- I have been tossing around the idea (in my head) that it may be on account of some positive news for the silence. If they intend to make a real play for plus $1.00 per share, this would be the time for strategic moves. One can hope!
👍️0
JRoon71 JRoon71 9 hours ago
Skipper, I wonder if choosing not to pre-announce top-line results (as they have in the past) is strategic. Maybe they actually have something GOOD to announce, but want to save it for the ER CC. 🙏

Total speculation. Again, as always with Amarin/Sarissa, we never know what's going on.
👍️0
Number sleven Number sleven 10 hours ago
Skipper, I don't know.
Sleven,
👍️0
Skipperdog11 Skipperdog11 10 hours ago
Sleven, I'm not sure current management thinks Q4/2024 overall results warrant a press release. Is this getting late, or is it just me?
👍️0
JRoon71 JRoon71 10 hours ago
Ram, if you look at some of the approvals in Europe...Italy, France, and Germany come to mind...their approvals are so narrow in scope, and if you read their opinions (I have not read Germany's, but they obviously outright denied reimbursement), they state some hesitancy due to the mineral oil issue (among other issues). Now, they may just be using that as an excuse to narrow their scope of approval (on cost reimbursement), but they used it nonetheless. Italy's scope is extremely narrow, and France (which has not yet approved reimbursement), presented a very weak opinion on Vazkepa.

So, it seems that a confirmatory trial would have been helpful, at minimum, to gaining greater authorization for reimbursement. Unfortunately, MITIGATE blew up, and maybe that was going to be the additional "proof" that we needed. But here we are.
👍️ 1
Number sleven Number sleven 10 hours ago
Triple, Again thanks. That is the document I found. I was unable to copy it.
Sleven,
👍️0
Number sleven Number sleven 10 hours ago
Triple, Thank you. Would be nice to have some details. I guess our current management doesn't think a label change is important enough for a press release.
Sleven,
👍️0
Triple88 Triple88 11 hours ago
https://ec.europa.eu/health/documents/community-register/2025/20250123165277/dec_165277_en.pdf
👍️0
Triple88 Triple88 11 hours ago
NS7 looks like AMRN's request was approved so should be positive

"Having regard to the changes to the terms of the decision granting the marketing
authorisation requested by Amarin Pharmaceuticals Ireland Limited in accordance with
Regulation (EC) No 1234/2008 and in accordance with Article 61(3) of Directive
2001/83/EC"
👍️0
Number sleven Number sleven 11 hours ago
It looks like there has been an amendment to our European marketing authorization. 1-23-2025. Anyone have any details?
Sleven,
👍️0
ramfan60 ramfan60 11 hours ago
Thanks for making my point...... it's a requirement in China for continued approval so of course it needs to be done. Unless it's a requirement elsewhere, it's a waste of time and money.
👍️0
rosemountbomber rosemountbomber 12 hours ago
An example of a private company (not listed on the exchange) in cardio space being bought by Novartis before phase 3 results:

https://www.thepharmaletter.com/novartis-to-boost-cardio-pipeline-with-anthos-therapeutic-buy
👍️0
DMC8 DMC8 16 hours ago
Acadian Asset Management Llc
https://fintel.io/so/us/amrn/acadian-asset-management-llc
👍 5
Whalatane Whalatane 19 hours ago
Ram its well established the confirmatory trials increase prescription rates .
AMRN does not need to run a full R-IT trial . Just a trial in the highest risk patients , large enough ( properly powered ) to generate stat sig results in the shortest time possible .
The R-IT trial was stat sig with a P value of .01 at around 24 mths .....my guess based on published data
Eddings market approval in China is conditioned on them running a confirmatory trial with Chinese patients . This trial has to prove efficacy within 5 yrs of their initial approval ...so 4.5 yrs left ....for them to maintain the right to sell Vascepa in China .
So that trial is certainly not a waste of time and money .
They need it

Kiwi
👍️0
ramfan60 ramfan60 21 hours ago
Kiwi, the point is none of this matters unless the countries holding out approval are saying.......we don't believe Reduce-It therefore you need another study to prove it and then we will will approve. Nobody is saying that so Reduce-It 2.0 is a waste of time and money until that happens.
👍️0
Nukemtiltheyglow Nukemtiltheyglow 1 day ago
If it's not designed or made in France, forget about it. Like the Monty Python skit "Holy Grail", "I spit in your general direction, you silly man."
👍️0
Whalatane Whalatane 1 day ago
Impact of follow up trials
Cardiovascular Medications Impact: Cardiovascular disease (CVD) medications represent a significant portion of Medicare spending due to their high prevalence among older adults.
For example, Eliquis, a leading cardiovascular drug for stroke prevention in atrial fibrillation, saw its gross Medicare Part D spending increase from $5 billion in 2018 to $12.6 billion in 2021.
This increase reflects both expanded use and confidence in its efficacy post-approval7.

Following the approval of Eliquis (apixaban), several follow-up clinical trials and real-world studies were conducted to evaluate its efficacy and safety across different indications and patient populations.

Below is a summary of these efforts:
Key Follow-Up Trials and Studies

Clinical Trials
ADVANCE Program:
Supported the approval of Eliquis for deep vein thrombosis (DVT) prophylaxis after hip or knee replacement surgery.
Included three randomized trials with over 11,000 patients comparing Eliquis to enoxaparin2.
ARISTOTLE and AVERROES Trials:
ARISTOTLE: Compared Eliquis to warfarin in 18,201 patients with nonvalvular atrial fibrillation (NVAF) and demonstrated superior stroke/systemic embolism prevention with lower bleeding risk45.
AVERROES: Compared Eliquis to aspirin in 5,598 NVAF patients unsuitable for warfarin, showing significant benefits in stroke prevention45.
Open-Label Extension of AVERROES:
Evaluated long-term safety and efficacy outcomes for patients continuing apixaban use until regulatory approvals were finalized6.

Real-World Evidence Programs

ACROPOLIS Program:
A global real-world data initiative analyzing outcomes from over 20 databases involving more than two million patients in 10+ countries.
Focused on safety, effectiveness, hospitalization rates, and healthcare costs associated with Eliquis in routine clinical practice13.
Elderly Patient Studies:
Retrospective analyses comparing Eliquis to warfarin in elderly NVAF patients. These studies highlighted its favorable safety profile with lower bleeding risks10.
Cancer-Associated VTE Analysis:
Real-world data showed that Eliquis had a lower rate of recurrent venous thromboembolism (VTE) compared to low molecular weight heparin (LMWH) in cancer patients, with similar bleeding risks1.
Switching Studies:
Observational studies examined the impact of switching between direct oral anticoagulants (DOACs) like Eliquis and rivaroxaban, assessing outcomes such as stroke, systemic embolism, and bleeding risks9.

These follow-up efforts have provided robust evidence supporting the use of Eliquis across diverse patient populations and settings while addressing safety concerns observed during transitions or long-term use.


Kiwi
👍️0
DMC8 DMC8 1 day ago
https://stocktwits.com/SanDiegoLiving/message/603797665
👍️0
Whalatane Whalatane 1 day ago
Some more on how confirmatory trials increase prescriptions
Increased Prescriber Confidence:
For example, trials like CAMELOT demonstrated that antihypertensive drugs such as amlodipine significantly reduced adverse cardiovascular events compared to placebo (hazard ratio 0.69; 95% CI, 0.54–0.88), reinforcing their effectiveness and encouraging physicians to prescribe them more frequently

Economic and Policy Implications: Confirmatory trials often influence reimbursement policies and pricing negotiations, making drugs more accessible.
For instance, Medicare spending on drugs often increases after confirmatory trial results support their efficacy, as seen with cardiovascular medications post-approval

Marketing and Awareness: Positive trial results are frequently used in marketing campaigns, raising awareness among both doctors and patients about the drug’s benefits, which can further drive prescriptions.

In summary, confirmatory trials provide the necessary evidence to establish trust in a drug's efficacy and safety, leading to increased prescriptions through regulatory approval, prescriber confidence, and broader accessibility.

Kiwi
👍️0
DAR53 DAR53 1 day ago
CaptBeer, thanks again for all you do. Amarinians, we need to bombard Amarin and Sarissa with communications supporting CaptBeer as head of marketing/marketing support. The informative and professional charts CaptBeer continues to send out should be spread to a greater mass of people, both US and ROW. Again, CB, great job!
👍 1
Whalatane Whalatane 1 day ago
Positive confirmatory clinical trials significantly increase drug prescription rates by providing robust evidence of a drug's efficacy and safety.
Here are the main ways this occurs:

Increased Provider Confidence: Positive trial results validate the clinical benefits of a drug, leading healthcare providers to prescribe it more frequently. This is particularly true for drugs initially approved based on surrogate endpoints, as confirmatory trials demonstrate real-world patient outcomes

Conversion to Regular Approval: Drugs that successfully complete positive confirmatory trials often transition from accelerated to regular approval. This regulatory milestone reassures prescribers and patients about the drug's reliability, further boosting its usage

Broader Indications: Positive results can lead to expanded indications, such as earlier lines of therapy or broader patient populations, which naturally increase prescription rates
.
Market and Policy Impact: Positive trials enhance a drug's reputation in the marketplace, encouraging payers to cover it more widely and reducing hesitancy among prescribers

In summary, positive confirmatory clinical trials play a critical role in driving higher prescription rates by solidifying trust in a drug's clinical value and expanding its approved uses.


You think Statins would be so widely prescribed based on its first clinical trial ?
No way
.
3 Cardiovascular Drugs
Some cardiovascular drugs have seen increased adoption following confirmatory Phase III trials that validated their impact on hard clinical endpoints like reducing heart attacks or strokes.
For example:
Statins gained widespread use after large-scale trials demonstrated their ability to lower LDL cholesterol and reduce cardiovascular events in diverse populations.
Kiwi
👍️0
DAR53 DAR53 1 day ago
CaptBeer, thanks again for all you do. Amarinians, we need to bombard Amarin and Sarissa with communications supporting CaptBeer as head of marketing. The informative and professional charts CaptBeer continues to send out should be spread to a greater mass of people, both US and ROW. Again, CB, great job!
👍️ 4
JRoon71 JRoon71 1 day ago
Unfavorable opinion on reimbursement in other populations of the indication including patients with severe hypertriglyceridemia (≥ 500 mg/dL) and those with diabetes and at least one other cardiovascular risk factor (primary prevention).

And why are they still recommending fibrates as first line of secondary care after statins? And should not combine with fibrates, PCSK9's, or Ezetimibe. And also not recommended for severe hypertriglyceridemia or those with diabetes.

Can't find anything on status of reimbursement. But not real fond of their narrative on Vazkepa.
👍️0
seve333 seve333 1 day ago
Probably. His predictions have all been wrong so far.
👍️0
CaptBeer CaptBeer 1 day ago
The French HAS Transparency Committee are a bunch of morons.
👍 1
rosemountbomber rosemountbomber 1 day ago
Of course we will never know whether the rumours of BP interest had any substance to them, or whether the stories that JT's ask was so high it deterred them all. But to be honest about it, BP deals with patent and generic challenges all the time and if there wasn't an ongoing challenge on the table there was no way of knowing whether one would comr along.  I don't think many here think that BP couldn't have handled the challenge differently. 
👍️ 1
ramfan60 ramfan60 1 day ago
Kiwi, you can't tell anyone with certainty that doing more trials to confirm the Reduce_It study results will change anything with regards to approval and reimbursement decisions either so why bother! If that was a known criteria for acceptance, don't you think it would be happening already? Stop beating that drum.
👍️0
Number sleven Number sleven 1 day ago
RMB,
https://www.has-sante.fr/jcms/fc_2875171/fr/resultat-de-recherche?text=Vazkepa+&tmpParam=&opSearch=
Sleven,
👍️0
Birdbrain Ideas Birdbrain Ideas 1 day ago
He meant after a 1 for 200 reverse split.
👍️0
Birdbrain Ideas Birdbrain Ideas 1 day ago
I don't think it could be sold before the patent dispute was resolved. No Big Pharma would sweep it up knowing that what happened was a possibility.
👍️0
Whalatane Whalatane 1 day ago
Thx ...by the way this used to be my lipid profile even on max dose statins
HDL in the low 30's with TG's over 150 mg /dl and LDL around 120 mg /dl

So the NNT ( numbers needed to treat ) is only 10 with a RRR of 42 % .

Dont tell me Amarin can't find a health dept somewhere in the UK / EU to run a small trial 2,000 - 3,000 for patients with this lipid profile ....to confirm these R-IT results .
Even if the results came back only half as good ...NNT of 20 with an RRR of 21% ......it would IMHO drastically increase prescription numbers

Kiwi
👍️0
seve333 seve333 1 day ago
No offence but you also said Brave was going to make this a 100 dollar stock. Your predictions so far are not too great.
👍️0

Your Recent History

Delayed Upgrade Clock